Distinct infectivity and neutralization antibody responses in the highly homologous AAV Go.1 and AAV5
Our findings highlight the potential of rAAV Go.1 as an improved gene therapy vector with superior transduction efficiency and enhanced immune evasion. The identified VP1 mutations further optimize viral properties, making rAAV Go.1 a promising candidate for future therapeutic applications.
Authors
- Hongxia Ma (ORCID: https://orcid.org/0000-0002-4477-613X)
- Hanbing Wang (ORCID: https://orcid.org/0000-0002-7835-2810)
- Yunling Gao (ORCID: https://orcid.org/0000-0002-6622-3253)
- Mei Li (ORCID: https://orcid.org/0000-0002-1742-2360)
- Yang Wu
- Jie Wang (ORCID: https://orcid.org/0000-0002-2997-3450)
Institutions
- Shanghai Jiao Tong University (CN)
- First People's Hospital of Foshan (CN)
- Songjiang District Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-04-04
- DOI
- https://doi.org/10.3389/fmed.2025.1554449
- Citations
- 2
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.63
Funders
- National Natural Science Foundation of China